Over the past twenty-five years, Obesity rates have spiraled to the level nearly 5 hundred million individuals worldwide. The United States leads the world, with a startling 31 % of the population being termed obese.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
Approval for weight loss drugs is significant in light of the fact that the FDA has not approved any drugs for weight loss in the past 10 years. Thus the weight loss pill passed FDA approval under considerable scrutiny. Qsymia is a combination drug, two drugs working together as one. Both of these drugs have enjoyed various rates of success in weight loss therapy. It was the innovative approach of Vivus to put them together.
As far as Food and Drug Administration commendation; clinical trials show the drug to perform markedly better than its competition's offerings. In two freestanding trial reviews; patients on Qsymia for one year, lost 6.7 per cent of their body weight in one study, and 8.9 percent in the other study. Patients on the strongest formula lost 11% of their weight, with trial subjects reporting annual weight loss of as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
The medical costs directly associated with obesity are nearly impossible to calculate, simply because multiple health problems and risks are associated with the condition. The preventable health problems associated with obesity include high blood pressure, stroke, heart attack and diabetes.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
Approval for weight loss drugs is significant in light of the fact that the FDA has not approved any drugs for weight loss in the past 10 years. Thus the weight loss pill passed FDA approval under considerable scrutiny. Qsymia is a combination drug, two drugs working together as one. Both of these drugs have enjoyed various rates of success in weight loss therapy. It was the innovative approach of Vivus to put them together.
As far as Food and Drug Administration commendation; clinical trials show the drug to perform markedly better than its competition's offerings. In two freestanding trial reviews; patients on Qsymia for one year, lost 6.7 per cent of their body weight in one study, and 8.9 percent in the other study. Patients on the strongest formula lost 11% of their weight, with trial subjects reporting annual weight loss of as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
About the Author:
Are you looking to find out if Qsymia Capsules are available around you? We all will have to get a prescription to get the Qsymia diet pills
No comments:
Post a Comment